SEC Company Response from CNBX Pharmaceuticals (CNBX) — Jul 28, 2015
CNBX Pharmaceuticals Inc.
Date: July 28, 2015 · CIK: 0001343009 · Accession: 0001019687-15-002887
AI Filing Summary & Sentiment
File numbers found in text: 000-52403
Letter
Re: Cannabics Pharmaceuticals Inc. Form 10-K for the Fiscal Year Ended August 31, 2014 Filed December 15, 2014 File No. 000-52403
Dear Ms. Marlowe,
The Issuer is currently preparing its responses to your above-referenced Comments. Pursuant to our conference call with your staff as well as my separate conference call with the legal staff, we are attempting to definitively respond to your last comments inclusive of our draft 10-KA, which is encompassing more time than we had expected due to the technicality of some of the issues.
We would expect to have these responses and draft 10-KA presented to you by Monday 10th August. Should you have any questions or comments, please do contact me at any time. Thank you for your understanding in this matter.
Sincerely yours,
David E. Price,
Esq.
Show Raw Text
CORRESP 1 filename1.htm #3 BETHESDA METRO CENTRE SUITE 700 BETHESDA, MD 20814 --------- Tel (877) 424-2429 Cannabics.com 29th July, 2015 US Securities & Exchange Commission Corporate Finance Division Washington, DC 20549 Attn: Ms. Julie Marlowe Re: Cannabics Pharmaceuticals Inc. Form 10-K for the Fiscal Year Ended August 31, 2014 Filed December 15, 2014 File No. 000-52403 Dear Ms. Marlowe, The Issuer is currently preparing its responses to your above-referenced Comments. Pursuant to our conference call with your staff as well as my separate conference call with the legal staff, we are attempting to definitively respond to your last comments inclusive of our draft 10-KA, which is encompassing more time than we had expected due to the technicality of some of the issues. We would expect to have these responses and draft 10-KA presented to you by Monday 10th August. Should you have any questions or comments, please do contact me at any time. Thank you for your understanding in this matter. Sincerely yours, David E. Price, Esq.